To address this question, the TRAIL-resistant erythroleukemia (K562) cells and human promyelocytic leukemia (HL-60) cells [26] were used to detect the antitumor ability of sTRAIL:FeSOD. This evidence concerns the gene TNFSF10 and acute promyelocytic leukemia.